<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00659321</url>
  </required_header>
  <id_info>
    <org_study_id>NIASPAN-DD-2005</org_study_id>
    <nct_id>NCT00659321</nct_id>
  </id_info>
  <brief_title>Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome</brief_title>
  <official_title>Placebokontrollierte Untersuchung Zur Wirkung Von Nikotinsäure Auf Die Dyslipidämie Bei Metabolischem Syndrom Und Das Arterioskleroserisiko (Placebo Controlled Investigation of Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome and the Risk of Atherosclerosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <brief_summary>
    <textblock>
      Placebo controlled evaluation of effectiveness of nicotine acid in treatment of postprandial
      dyslipidemia in patients with metabolic syndrome. Nicotine acid decreases postprandial
      hyperlipidaemia in patients with metabolic syndrome which reduces the low-grade inflammation
      and the risk of atherosclerosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo controlled evaluation of effectiveness of nicotine acid in treatment of postprandial dyslipidemia in patients with metabolic syndrome</measure>
    <time_frame>after 16 weeks treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Dyslipidaemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>16 weeks treatment with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nicotine acid</intervention_name>
    <description>16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>16 weeks treatment with placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  dyslipidemia (triglycerides &gt;= 150 mg/dl and/or decreased levels of HDL-cholesterol
             &lt;40 mg/dl in men or &lt; 50 mg/dl in women)

          -  further components of the metabolic syndrome: Hypertension: blood pressure &gt;= 130/85
             mmHg or/and Hyperglycemia: fasting plasma glucose &gt;= 100 mg/dl or/and 2 hour plasma
             glucose after 75g glucose load (OGTT) &gt;= 140 mg/dl or/and Obesity: waist
             circumferences &gt; 102 cm in men or &gt;88 cm in women

        Exclusion Criteria:

          -  Contraindication and incompatibility of nicotine acid

          -  Patients with ulcus ventriculi or ulcus duodeni

          -  Intake of lipid lowering drugs &lt; 6 weeks before randomization

          -  therapy of type 2 diabetes with insulin, glitazones, acarbose or more than one
             antidiabetic drug (only mono-therapy with metformin or sulfonyl urea is permit) - no
             acceptable therapy of diabetes with levels of HbA1C&gt;=8.0%

          -  cardiovascular events in the last 6 months

          -  chronic inflammatory diseases (lupus erythematodes, arthritis, morbus Crohn or colitis
             ulcerosa)

          -  ALAT elevation 2.5 times more than the normal limit

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markolf Hanefeld, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GWT-TUD GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GWT-TUD GmbH, Centre for Clinical Studies</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2008</study_first_submitted>
  <study_first_submitted_qc>April 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2008</study_first_posted>
  <last_update_submitted>January 10, 2012</last_update_submitted>
  <last_update_submitted_qc>January 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

